Latest Advances in Lung Cancer Research

FDA grants breakthrough designation to FoundationOne Tracker, an assay for detecting MRD in cancer, aiding treatment decisions and relapse monitoring.

Medicare expands LDCT lung cancer screening eligibility, lowering age to 50 and pack-year history to 20, streamlining processes to improve early detection.

Lung cancer in never smokers presents unique molecular traits and lower mutation burdens, necessitating distinct treatment strategies and revised screening criteria.

A study developed and tested a remote intervention to improve the quality of life for lung cancer patients transitioning to post-treatment surveillance.

American Cancer Society report shows lung cancer deaths decline, boosting overall cancer survival despite persistent disparities and need for better screening.

FDA grants breakthrough designation to CLN-081, a targeted therapy for NSCLC with EGFR exon 20 mutations, showing promise in ongoing clinical trials.

Mount Sinai study shows earlier lung cancer diagnosis via CT screening significantly reduces deaths, underscoring the need for widespread screening adherence.

Most never-smokers’ lung tumors have targetable mutations matched to FDA-approved drugs, unlike smokers’ tumors. Testing is critical.

Rare EGFR exon insertions in lung cancer allow targeted therapies, but resistance develops; new drugs help.

Biomarker testing decisions for lung cancer vary by type of clinician. Fewer community oncology clinicians use biomarker testing.

[NEED EXTERNAL LINK TO ARTICLE]

Imfinzi plus chemotherapy tripled patient survival at three years in the CASPIAN Phase III trial for patients with extensive-stage SCLC.

Racial Disparities in Lung Cancer: Research shows racial disparities in treatment and survival between Black and White lung cancer patients.